Table 2.

Patients with stage 1B2 cervical cancer who failed to undergo VRT and pelvic lymph node dissection after neoadjuvant chemotherapy

Patient	Age, yr	Histology	Grade	Invasion depth, mm	Tumor size, mm	Lymph nodes	LVSI	Cycles of NACT	Path response to NACT	Treatment instead of VRT	Reason	Recurrence	Treatment recurrence	DFS, months	OS, months	Current status
1a	25	SCC	2	11	30	3/23	Yes	3/6	Partial	Chemo‐radiation	Mets lymph nodes	No	n/a	87.9	87.9	NED
2	27	AC	2	9	25	0/15	Yes	4/6	Partial	Rad hys	Poor response to CT	Yes	Debulking + RT	17.0	85.9	NED
3b	30	AC	2	4	25	0/20	No	4/6	Complete	Rad hys	Poor response to CT	No	n/a	13.1	13.1	NED
4	31	SCC	3	10	35	0/21	No	6/6	Partial	Rad hys	Poor response to CT	No	n/a	14.7	14.7	NED

All patients had stage IB2 and received cisplatin/carboplatin and paclitaxel (70 mg/m²) as NACT.

^aPatient received chemoradiation because of macrometastases in right obturator pelvic lymph nodes.

^bResponse evaluated as poor response after examination under anesthesia; magnetic resonance imaging showed no residual disease. On final histology no residual disease after neoadjuvant chemotherapy. Abbreviations: AC, adenocarcinoma; CT, chemotherapy; DFS, disease‐free survival; LVSI, lymph vascular space invasion; Mets, metastases; n/a, not applicable; NACT, neoadjuvant chemotherapy; NED, no evidence of disease; OS, overall survival; Path response to NACT, pathological response after surgery; Rad hys, radical hysterectomy; RT, radiotherapy; SCC, squamous cell carcinoma; VRT, vaginal radical trachelectomy.